RBI Spends Record Reserves Defending Rupee, Faces $100 Billion Test

What RBI's currency defense changed

The Reserve Bank of India has been selling dollars from its foreign exchange reserves at a record pace to stop the rupee from falling too fast, and the bill for that defense is now large enough that the central bank is said to face a further 100 billion dollar test in holding the line. Central banks step in this way when a currency is under sustained selling pressure, usually from foreign investors pulling money out, importers buying dollars, or global risk aversion. Every dollar RBI sells to support the rupee comes straight out of its reserves, so a record intervention means reserves have been drawn down by a meaningful amount already, with the fight not obviously over.

This is not a story about a company. It is a story about the exchange rate itself, which is one of the biggest swing factors for Indian businesses that either earn in dollars or pay for imports in dollars. Reliance Industries aside, the two clearest groups of NSE and BSE companies exposed to this are IT exporters and pharmaceutical companies that sell into the US, and airlines that pay for fuel and aircraft leases in dollars.

Why it matters for IT and pharma exporters

IT services companies bill most of their revenue in dollars but report profit in rupees, so when the rupee comes under pressure and eventually gives ground, each dollar of revenue converts into more rupees. The same logic applies to pharmaceutical companies with large US generics businesses, where dollar sales translate into a rupee-denominated topline and bottom line. A defended, more stable rupee blunts that currency tailwind in the short run, but the scale of RBI's intervention signals real underlying pressure on the currency, and that pressure is the kind of backdrop that has historically ended up supporting exporter margins once any defense eases.

The other side of the ledger is dollar cost exposure. Airlines lease aircraft and buy jet fuel in dollars, so a rupee under strain is a direct cost risk even before it shows up in the price of a ticket.

Which stocks, and why

Among IT majors, Tata Consultancy Services, Infosys, Wipro, HCL Technologies and Tech Mahindra all earn the bulk of their revenue in dollars from US and European clients, so sustained rupee weakness is a modest earnings tailwind for each, though the size of the benefit depends on how much of that weakness actually plays out versus how much RBI manages to contain.

In pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and Cipla all have sizeable US generics businesses, so the same currency mechanics apply to their dollar revenue lines.

On the other side, InterGlobe Aviation, which runs IndiGo, carries meaningful dollar costs through aircraft leases and jet fuel, so a rupee under pressure raises its cost base even if RBI's defense is currently cushioning the scale of that hit.

What to watch

The clearest signals to track are RBI's reserve numbers each week, which show whether the central bank is still spending at the same pace or slowing down, and the actual level of the rupee against the dollar. If reserves keep falling sharply while the rupee still weakens, that points to a currency under real strain rather than one that is comfortably defended. FII flow data is also worth watching, since sustained foreign outflows from Indian equities and bonds are usually the pressure RBI is fighting in the first place.